We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Stethoscope Spots Heart Valve Disease Earlier Than GPs

By HospiMedica International staff writers
Posted on 12 Feb 2026

Valvular heart disease affects more than half of people over 65, yet it often goes undiagnosed until symptoms become severe. More...

In advanced stages, untreated cases can carry a mortality risk of up to 80% within two years. Current diagnosis relies on echocardiography, which is costly and not suitable for widespread screening, while traditional stethoscope exams frequently miss cases. Now, a new study suggests that artificial intelligence (AI) could detect serious valve disease years earlier by analyzing heart sounds, offering a scalable screening approach.

Researchers at the University of Cambridge, UK) developed an AI algorithm trained on heart sound recordings from 1,767 patients who also underwent echocardiography, the gold standard reference test. Using digital stethoscopes, the team captured short audio samples and trained the algorithm directly on echocardiogram results rather than on heart murmurs alone. This approach enabled the system to identify subtle acoustic patterns associated with valve disease, even in cases without obvious murmurs.

The AI correctly identified 98% of patients with severe aortic stenosis and 94% of those with severe mitral regurgitation. When compared against 14 general practitioners who reviewed the same recordings, the algorithm consistently outperformed every clinician. The results, published in npj Cardiovascular Health, showed that the system minimized false alarms while maintaining high accuracy, particularly for severe disease. The findings indicate that AI-assisted auscultation could provide reliable detection in primary care settings.

The technology is designed as a rapid screening tool to help doctors decide which patients require referral for echocardiography. Only a few seconds of heart sound recording are needed, and minimal training is required to operate the device. Researchers emphasize that further trials in real-world GP settings are necessary before widespread rollout, particularly to improve detection of moderate disease. If validated, the tool could ease pressure on healthcare systems and enable earlier intervention before irreversible heart damage occurs.

“Valve disease is treatable. We can repair or replace damaged valves and give people many more years of healthy life. But timing is everything,” said Professor Rick Steeds, co-author of the study. “Simple, scalable screening tools like this could make a real difference by finding patients before irreversible damage occurs.”

Related Links:
University of Cambridge


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.